News - Page 69 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Panel: Psychedelic VCs Reflect on 2022

Panel: Psychedelic VCs Reflect on 2022

Post published:January 24, 2023
Post category:2022 Year in Review

Read more about the article Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Psyence and Eden Labs Announce Extraction and Product Development Collaboration

Post published:January 24, 2023
Post category:Press Release

Read more about the article Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Post published:January 23, 2023
Post category:Press Release

Read more about the article Psychedelic Funding in 2022

Psychedelic Funding in 2022

Post published:January 23, 2023
Post category:2022 Year in Review

Read more about the article Rick Doblin – The Balance at MAPS Between Public Benefit and Private Profit

Rick Doblin – The Balance at MAPS Between Public Benefit and Private Profit

Post published:January 23, 2023
Post category:2022 Year in Review

Read more about the article Psychedelics in the Public Markets: 2022

Psychedelics in the Public Markets: 2022

Post published:January 20, 2023
Post category:2022 Year in Review

Read more about the article The Psychedelic Value Chain

The Psychedelic Value Chain

Post published:January 20, 2023
Post category:2022 Year in Review

Read more about the article Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

Post published:January 20, 2023
Post category:Press Release

Read more about the article Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™

Post published:January 20, 2023
Post category:Press Release

Read more about the article Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Post published:January 20, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.